Part of our series: Spring ’26 in Pharma — Through a Salesforce Architect’s Lens

TL;DR — Key Takeaways

1. Most life sciences organizations are running AI pilots. Very few have scaled them into production workflows.
2. The gap between piloting and operationalizing comes down to three things: governed data, formalized processes, and cross-functional adoption.
3. The most common thing Jeff Sumption hears when meeting a new client: “our data is a mess.” That problem has to be solved before AI can scale.
4. AI maturity in life sciences is not about the sophistication of the model. It is about the infrastructure around it.
5. Organizations that scale AI successfully treat documentation and audit readiness as a design requirement, not an afterthought.

Every life sciences organization running an AI pilot right now thinks they are close to scaling it.

Most of them are not.

The technology is rarely the problem. The models work. The Salesforce infrastructure is capable. The use cases — prior authorization intake, benefit verification, enrollment support — are well understood. We covered one of them in detail in Spoke 2A: How AI Is Changing Prior Authorization in Life Sciences.

What stops organizations from scaling is everything that surrounds the model. The data it depends on. The processes it has to fit into. The teams that have to trust it enough to actually change how they work.

Get those three things right, and AI scales. Get them wrong, and you keep running pilots forever.

(This blog is part of our Month 2 series on AI and agents in healthcare. Start with the hub: AI Can’t Make the Call — Here’s Why That’s Actually the Point.)

What separates organizations that experiment with AI from those that operationalize it?

The difference comes down to data, process, and people — in that order.

Jeff Sumption, Salesforce Solution Architect at CI Digital, hears the same thing almost every time he walks into a new client engagement:

— Jeff Sumption, Salesforce Solution Architect, CI Digital

That observation matters more than most organizations want to admit. AI does not fix bad data — it amplifies it. If the underlying records are incomplete, inconsistent, or siloed across systems, the model will surface incomplete, inconsistent, and siloed outputs. Faster than before, but no more useful.

The organizations that have moved past experimentation did not start with the most sophisticated models. They started with clean, governed data. Then they built from there.

Why do so many life sciences AI pilots fail to reach production?

Most pilots fail to reach production because they are designed to prove the technology works, not to prove the organization is ready for it.

A pilot is easy to control. You pick a narrow use case, feed it clean sample data, run it in a contained environment, and show stakeholders a promising result. That result is real. But it does not tell you whether your production data is clean enough to support the model at scale. It does not tell you whether your workflow owners will actually adopt the new process. And it does not tell you whether your compliance team can document what the model did in a way that satisfies an auditor.

Those are the questions pilots rarely answer. And they are exactly the questions that determine whether a proof of concept becomes a production service.

What infrastructure does AI actually need to scale safely in life sciences?

Scaling AI safely in life sciences requires four things beyond the model itself: enterprise-grade data governance, model lifecycle management, compliant infrastructure, and a workforce that knows how to use AI in their daily work.

Data governance means more than clean records. It means knowing where your data comes from, who has touched it, what transformations it has been through, and whether it meets the standards required for use in a regulated workflow. Without that foundation, every AI output is built on uncertain ground.

Model lifecycle management means you know which version of which model produced which output — and you can prove it on demand. In a regulated environment, “we updated the model” is not an acceptable explanation for a change in outputs. Every version needs to be tracked, validated, and documented.

Compliant infrastructure means the systems housing your AI workflows meet HIPAA requirements, support audit logging, and restrict data access appropriately. This is not optional. It is the baseline.

Workforce readiness means the people in your organization understand what AI can and cannot do — and trust it enough to integrate it into their daily work. That trust does not happen by accident. It has to be built through training, transparency, and early wins that demonstrate real value.

Scaling AI in life sciences starts with the architecture, not the algorithm. If your organization is stuck in pilot mode or struggling to move from proof of concept to production, CI Digital can help you identify what is missing and build a path forward. Let’s talk.

How should life sciences organizations build toward AI maturity?

The path to AI maturity in life sciences runs through governance first, scale second.

Jeff’s view on what strong AI governance looks like in practice is direct:

— Jeff Sumption, Salesforce Solution Architect, CI Digital

That framing shifts the conversation away from technology and toward operations. AI maturity is not a measure of how advanced your models are. It is a measure of how well your organization can manage them — deploy them responsibly, monitor them continuously, document them completely, and explain them clearly to any audience that asks.

The organizations that get this right treat documentation not as a compliance burden but as a design requirement. They produce clean audit trails by default. They can explain their AI use cases on demand. And when something goes wrong — because at scale, something eventually will — they have the processes in place to identify it, correct it, and show exactly what they did to fix it.

That is what mature looks like. And it is achievable. It just requires building the right foundation before you scale the model.

Frequently Asked Questions

What does it mean to operationalize AI in life sciences?

Operationalizing AI means moving beyond a controlled pilot into a production workflow that runs consistently, meets compliance requirements, and is adopted by the teams it is designed to support. It requires governed data, documented processes, and infrastructure that supports audit.

Why do most life sciences AI pilots fail to scale?

Most pilots are designed to prove the technology works, not to prove the organization is ready. They use clean sample data in controlled conditions. Production environments have messy data, resistant workflows, and compliance requirements that a pilot rarely surfaces.

What is AI maturity in pharma?

AI maturity in pharma is not about model sophistication. It is about organizational readiness — governed data, model lifecycle tracking, compliant infrastructure, documented processes, and a workforce that understands how to use AI responsibly in regulated workflows.

What role does data governance play in scaling AI on Salesforce?

Data governance is the foundation. Without knowing where your data comes from, who has touched it, and whether it meets regulatory standards, every AI output is built on uncertain ground. Clean, governed data is what separates organizations that scale from those that stay in pilot mode.

How does AI governance work in a healthcare organization?

Strong AI governance in healthcare means a real operating model: clear principles on patient safety and human oversight, defined roles and committees, documentation standards, and risk-based review processes. Higher-risk AI gets more rigorous validation. Lower-risk automation moves faster within defined guardrails.

What comes next in the AI workflow?

Once an organization has governed data, compliant infrastructure, and cross-functional buy-in, the next question is where to apply AI beyond back-office intake work.

Patient support programs are one of the most valuable and underutilized opportunities in life sciences. NLP has advanced far enough to pull key data from complex documentation accurately. Machine learning can process large volumes of data to surface potential coverage issues before they delay treatment. And specialized AI agents can handle routine communication without ever touching a clinical decision.

We cover this in depth in the next blog in this series.

Up Next in the Series: AI in Patient Support Programs: Where It Helps and Where It Has to Stop

Patient support programs are one of the most underutilized opportunities in life sciences AI. The next blog covers where AI genuinely helps \u2014 and where it has to hand off to a human. Link coming soon.

Up Next:

→ AI in Patient Support Programs: Where It Helps and Where It Has to Stop (coming soon)

This post is part of our Spring ’26 series. Read the full overview: Spring ’26 in Pharma — Through an Architect’s Lens.

Not sure if your Salesforce architecture is ready for AI at scale? Connect with the CI Digital team and let’s find out together. Get in touch.